{"organizations": [], "uuid": "d9f8a7eb6e51b7fd921838196a7b69fa1ab49a18", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-corbus-pharmaceuticals-reports-q1/brief-corbus-pharmaceuticals-reports-q1-loss-per-share-0-21-idUSASC0A1EY", "country": "US", "domain_rank": 408, "title": "BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T15:13:00.000+03:00", "replies_count": 0, "uuid": "d9f8a7eb6e51b7fd921838196a7b69fa1ab49a18"}, "author": "", "url": "https://www.reuters.com/article/brief-corbus-pharmaceuticals-reports-q1/brief-corbus-pharmaceuticals-reports-q1-loss-per-share-0-21-idUSASC0A1EY", "ord_in_thread": 0, "title": "BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "corbus pharmaceuticals holdings inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "corbus pharmaceuticals holdings inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10, 2018 / 12:14 PM / Updated 11 minutes ago BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21 Reuters Staff\nMay 10 (Reuters) - Corbus Pharmaceuticals Holdings Inc :\n* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * CORBUS PHARMACEUTICALS HOLDINGS INC Q1 SHR LOSS $0.21\n* CORBUS PHARMACEUTICALS HOLDINGS INC Q1 SHR VIEW $-0.14 â€” THOMSON REUTERS I/B/E/S\n* CORBUS PHARMACEUTICALS HOLDINGS INC - EXPECTS TO REPORT TOPLINE RESULTS FOR PHASE 2B CF STUDY IN FIRST HALF OF 2020.\n* CORBUS PHARMACEUTICALS - EXPECTS CURRENT CASH AND CASH EQUIVALENTS WITH OTHER PAYMENTS TO FUND OPERATIONS THROUGH Q4 2019\n* CORBUS PHARMACEUTICALS HOLDINGS INC - ENDED Q1 WITH APPROXIMATELY $71.0 MLN OF CASH AND CASH EQUIVALENTS\n* CORBUS PHARMACEUTICALS HOLDINGS INC - REVENUE FOR QUARTER DECREASED BY APPROXIMATELY $0.3 MLN TO $1.0 MLN FROM QUARTER ENDED MARCH 31, 2017 Source text for Eikon: ", "external_links": [], "published": "2018-05-10T15:13:00.000+03:00", "crawled": "2018-05-10T15:28:28.016+03:00", "highlightTitle": ""}